Less Ads, More Data, More Tools Register for FREE

Pin to quick picksN4 Pharma Plc Regulatory News (N4P)

  • There is currently no data for N4P

Issue of Equity

23 Jun 2016 07:00

ONZIMA VENTURES PLC - Issue of Equity

ONZIMA VENTURES PLC - Issue of Equity

PR Newswire

London, June 22

Onzima Ventures PLC("Onzima" or the "Company")

Exercise of WarrantsIssue of Equity

23 June 2016

The Company announces that, pursuant to the exercise of all of the Broker Warrants in issue, it has issued 4,051,815 new ordinary shares of 0.1p each at 0.7p per share (“Warrant Shares”) raising approximately £28,000 for the Company.

Application will be made for admission of the Warrant Shares, which will rank pari passu in all respects with the Company's existing issued ordinary shares, to trading on AIM and it is expected that admission will occur and that dealings will commence at 8.00 a.m. on 28 June 2016.

For the purposes of the Financial Conduct Authority's Disclosure and Transparency Rules, the Company announces that following the issue of the Warrant Shares, the Company will have 181,956,558 Ordinary Shares in issue.

The Company has no ordinary shares held in treasury. The total number of voting rights in the Company will therefore be 181,956,558. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For further information please contact:

Onzima Ventures PLC Gavin Burnell, Luke CairnsTel: +44 (0) 1732 366561
Nominated Adviser Cairn Financial Advisers LLP Sandy Jamieson, Liam Murray Tel: +44 (0) 20 7148 7900
Broker Peterhouse Corporate Finance Limited Guy Miller, Lucy Williams Tel: +44 (0) 20 7469 0930
Date   Source Headline
17th Mar 202612:14 pmRNSResult of General Meeting and Change of Name
27th Feb 20267:00 amRNSNotice of GM and Proposed Change of Name
24th Feb 20267:00 amRNSCEO Appointment & Name Change Thalia Therapeutics
17th Dec 20257:00 amRNSBusiness and Operational Update
25th Sep 20257:00 amRNSInterim Results
23rd Sep 20257:00 amRNSPartnership with University of Strathclyde’s CMAC
22nd Sep 20257:00 amRNSN4 Pharma’s Nuvec® Targets Lung Cancer Cells
19th Sep 20257:00 amRNSNotice of Results, Analyst & Investor Presentation
11th Sep 20257:00 amRNS-RInvestor Event and Presentation
30th Jul 20251:55 pmRNS-RArticle on Nuvec®’s Potential in RNA Therapeutics
14th Jul 20257:00 amRNS-RInvestor Webinar
8th Jul 20257:00 amRNSDirectorate Change
30th Jun 20252:15 pmRNSResult of AGM
30th Jun 20257:00 amRNSAGM Statement
25th Jun 20257:00 amRNS-RInsight Event for Retail Investors
6th Jun 20257:00 amRNSFinal Results, Annual Report and Notice of AGM
27th May 20257:00 amRNS-REstablishment of New Senior Leadership Team
23rd May 202512:37 pmRNSTR-1: Notification of major holdings
21st May 20254:11 pmRNSHolding(s) in Company
15th May 20253:13 pmRNSChange of Registered Address
12th May 20257:00 amRNSN4 101 In Vivo Study Results
9th May 20258:24 amRNSHolding(s) in Company
29th Apr 20254:25 pmRNSHolding(s) in Company
29th Apr 202511:05 amRNSHolding(s) in Company
28th Apr 20252:30 pmRNSHolding(s) in Company
23rd Apr 20252:32 pmRNSTR-1: Standard form notification of major holdings
22nd Apr 202511:56 amRNSResult of General Meeting
4th Apr 20257:08 amRNSPosting of Circular and Notice of General Meeting
1st Apr 20254:08 pmRNSPlacing and Subscription to raise £1,750,000
18th Feb 202512:34 pmRNSHolding(s) in Company
7th Feb 20257:00 amRNS-RInvestor Webinar
27th Jan 20257:00 amRNS-RInvestor Webinar
16th Jan 20257:00 amRNS-RN4 Pharma Non-Executive Director Q&A
8th Jan 20257:00 amRNSDirectorate Changes
12th Dec 20247:00 amRNSN4 101 In Vitro Results
4th Dec 20247:00 amRNSNew Patent Filing
28th Nov 20247:00 amRNSGrant of Options
24th Sep 20247:00 amRNSInterim Results
17th Sep 20248:04 amRNSSRI Research Update
9th Sep 20247:00 amRNSDirector Appointment
23rd Aug 20248:30 amRNSChange of Auditor
20th Aug 20247:00 amRNSSRI Research Update
3rd Jul 20247:00 amRNSNanogenics Update
28th Jun 20247:00 amRNSTotal Voting Rights
19th Jun 20247:00 amRNSHolding(s) in Company
18th Jun 202412:34 pmRNSHolding(s) in Company
13th Jun 20244:52 pmRNSHolding(s) in Company
11th Jun 202411:16 amRNSNew Corporate Presentation
7th Jun 202410:18 amRNSPlacing and Subscription to raise £630,000
23rd May 20244:09 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.